

# Customer Information / Organizational Changes – USA

Information valid as of December 17, 2025

This document provides an overview of organizational and administrative changes related to the transition of Bioengineering's US activities following the acquisition by the Morimatsu Group. It is intended to support customers during the transition and serve as a reference document.

## 1. ORGANIZATIONAL UPDATE – BIOENGINEERING AND THE MORIMATSU GROUP

The acquisition of Bioengineering by The [Morimatsu Group](#) was completed successfully in September 2025. As a result, Bioengineering, Inc. (USA), a subsidiary of Bioengineering AG (Switzerland), will be dissolved as of December 31, 2025, and all business operations have ceased with immediate effect.

In order to continue serving our US customers locally, Pharmadule Morimatsu Inc. will assume the role of direct agent for Bioengineering AG moving forward.

As of December 15, 2025, Mr. James Stanfill, former Head of Operations of Bioengineering Inc., has assumed the role of Director of After-Sales within the Pharmadule Morimatsu Inc. organization in the United States.


We remain committed to providing our customers with exceptional products, service and support.

## 2. CONTINUITY

To our valued customers, the essence of our collaboration remains unchanged:

- Technical expertise, project experience, and support will continue at the same high level you have come to expect.
- Ongoing projects will continue without interruption.

Our objective is to ensure this transition is smooth, transparent, and as seamless as possible for you-



### 3. ORGANIZATIONAL CHANGES

Below is an overview of the relevant organizational and administrative adjustments:

#### **Inquiries and Quotations**

James Stanfill will continue to serve as your primary point of contact for all spare parts and service-related needs for Bioengineering products. His responsibilities include managing inquiries, providing detailed quotations, processing purchase orders, and confirming orders to ensure timely delivery and exceptional customer support throughout the process.

New product sales and support for Bioengineering equipment will also be supported by James Stanfill.

#### **Delivery and Invoicing**

Delivery and invoicing are provided by Bioengineering AG Switzerland. The customs duties will be paid by Bioengineering AG Switzerland.


Bioengineering AG  
Sagenrainstrasse 7  
8636 Wald  
Switzerland  
Tel: +41 55 256 81 11

#### **Bank details**

Bank:  
Zürcher Kantonalbank  
Bahnhofstrasse 9  
8001 Zurich  
Switzerland

Account number: 1300-9113.940

SWIFT / BIC: ZKBKCHZZ80A



#### 4. BENEFITS FOR THE CUSTOMER

By integrating into Morimatsu Pharmadule Inc., we are creating a stronger, more versatile organization designed to deliver greater value to you. This integration provides:

- Access to an expanded global network, ensuring broader reach and resources
- A more comprehensive portfolio of products, services and capabilities, tailored to meet diverse project needs and timelines
- A stable, long-term organizational foundation, reinforcing reliability and continuity

This marks an exciting chapter for our brand – one that significantly enhances our ability to serve you with greater efficiency, innovative solutions and long-lasting profitable equipment investments.

#### 5. CONTACT INFORMATION

James Stanfill  
Director of After-Sales  
[services@bioengineering-inc.com](mailto:services@bioengineering-inc.com)  
Office: 626 412 3233

We look forward to continuing our partnership with you based on trust, collaboration and long-term commitment.

Should you have any questions or require further information, please do not hesitate to contact us.

-----  
Roland Durner  
CEO  
Bioengineering AG, Switzerland

-----  
Gu Zhenghui  
Managing Director  
Pharmadule Morimatsu Inc., USA